Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) CEO Keith J. Sullivan sold 12,075 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $1.91, for a total value of $23,063.25. Following the transaction, the chief executive officer now owns 1,360,203 shares in the company, valued at approximately $2,597,987.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Neuronetics Stock Performance
Shares of STIM traded down $0.10 during mid-day trading on Thursday, hitting $1.90. The company’s stock had a trading volume of 140,122 shares, compared to its average volume of 168,938. Neuronetics, Inc. has a one year low of $1.03 and a one year high of $5.07. The company has a debt-to-equity ratio of 2.15, a quick ratio of 5.18 and a current ratio of 5.65. The firm has a market capitalization of $57 million, a PE ratio of -1.98 and a beta of 2.32. The stock’s 50-day moving average is $2.03 and its two-hundred day moving average is $3.06.
Neuronetics (NASDAQ:STIM – Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.06. Neuronetics had a negative return on equity of 75.84% and a negative net margin of 37.61%. The company had revenue of $17.42 million during the quarter, compared to analysts’ expectations of $17.10 million. As a group, sell-side analysts anticipate that Neuronetics, Inc. will post -0.91 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on STIM
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Worth Venture Partners LLC bought a new position in Neuronetics in the fourth quarter worth $30,000. SG Americas Securities LLC bought a new position in Neuronetics in the first quarter worth $62,000. Fielder Capital Group LLC bought a new position in Neuronetics in the fourth quarter worth $66,000. FNY Investment Advisers LLC bought a new position in Neuronetics in the fourth quarter worth $87,000. Finally, FourWorld Capital Management LLC bought a new position in Neuronetics in the first quarter worth $171,000. 53.59% of the stock is owned by institutional investors.
About Neuronetics
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Articles
- Five stocks we like better than Neuronetics
- Investing in large cap stocks: Diving into big caps
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- Airline Stocks – Top Airline Stocks to Buy Now
- Parabolic Rise of This Stock Shows No Signs of Slowing
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.